slides · global inventory
Metric
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 79,264
Current window 71,101-71,130
Pages 2,643
Rows per page 30
Component
71,101-71,130 of 79,264
147
Uses a combination of a chart from a company presentation and direct quotes from an SEC 10K filing to highlight a discrepancy.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
152
The slide uses a direct quote to undermine the technical viability of the company's core technology.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
158
The slide uses a 'villain' narrative by citing an ex-employee to undermine the company's core value proposition.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
178
The slide uses a historical stock chart to illustrate a previous crash as a warning for future performance.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
180
The slide uses data from CapitalIQ to support a bearish thesis regarding insider selling.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
183
The slide uses red boxes and arrows to draw attention to specific, aggressive growth figures in the financial table.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
187
Uses a quote from a VW employee to validate the argument.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
20
The slide uses direct excerpts from a medical paper to build a case against the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
34
The slide uses a screenshot of a Soleno clinical trial flow diagram to highlight patient drop-off.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
38
The slide uses an excerpt from the FDA label to critique the clinical trial design.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
39
The slide uses a red box to highlight a specific time period in the C602-RWP study to question the validity of the efficacy results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
41
The slide uses a 'villain' framing to question the validity of Soleno Therapeutics' clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
48
The slide uses a specific chart from a clinical paper to challenge the safety profile of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
49
Uses a red-annotated chart to highlight the discrepancy between reported LBM and suspected fluid retention.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
51
The slide uses visual evidence to argue for data fabrication in a clinical trial report.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
88
The slide highlights the gap between physician prescribing behavior (driven by patient pressure) and their actual clinical belief in the product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
114
The red box highlights the specific data point (Week 0 to Week 13) where the pooling occurs.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
115
The slide uses a red box and annotations to highlight the drop in sample size (n=125 to n=103) at week 13, suggesting data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
116
The slide uses a red box and arrow to draw attention to the increase in HbA1c between week 0 and week 13.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
117
The slide uses a line chart with error bars to argue that the mean value hides adverse patient outcomes. It highlights the 1-standard deviation range and extrapolates to 2-standard deviations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
118
The slide explicitly notes the re-graphing of data from a previous page to improve numerical accuracy on the time axis and clarity of standard deviation ranges.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
119
The slide uses a red box to highlight the specific comparison between placebo and pooled data at week 13.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
120
The slide uses a red box to highlight the specific data columns that demonstrate the increase in pre-T2D and T2D patient populations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
122
The slide uses red arrows and dots to visually demonstrate the discrepancy between cited data and the actual study graph.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
123
The slide uses a scatter plot with a linear regression line to refute a specific company claim regarding metabolic safety.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
125
The slide uses a red oval to highlight the baseline data point and a dashed red box to represent the pre-T2D threshold range.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
128
The slide highlights a 'cut-and-paste' error where the visual structure of the graph is identical between two sources, but the underlying data points (HbA1c values) have been altered.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
129
The slide uses visual annotations (red arrows and brackets) to highlight data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
132
The slide uses a line chart to demonstrate that the fasting glucose values are identical to a previous study (Miller et al 2024), implying the new HbA1c claims are fabricated.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
133
The slide highlights that GH induces insulin resistance while DCCR blocks insulin release, creating a synergistic risk for hyperglycemia.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit